171 related articles for article (PubMed ID: 30105523)
41. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III?
Song M; Yoon SB; Lee IS; Hong TH; Choi HJ; Choi MH; Lee MA; Jung ES; Choi MG
Eur J Cancer; 2018 Nov; 104():62-69. PubMed ID: 30326370
[TBL] [Abstract][Full Text] [Related]
43. The More the Better-Lower Rate of Stage Migration and Better Survival in Patients With Retrieval of 20 or More Regional Lymph Nodes in Pancreatic Cancer: A Population-Based Propensity Score Matched and Trend SEER Analysis.
Warschkow R; Widmann B; Beutner U; Marti L; Steffen T; Schiesser M; Schmied BM
Pancreas; 2017; 46(5):648-657. PubMed ID: 28196023
[TBL] [Abstract][Full Text] [Related]
44. Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis.
Beg MS; Gupta A; Sher D; Ali S; Khan S; Gao A; Stewart T; Ahn C; Berry J; Mortensen EM
Am J Clin Oncol; 2018 Aug; 41(8):766-771. PubMed ID: 28079594
[TBL] [Abstract][Full Text] [Related]
45. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
[TBL] [Abstract][Full Text] [Related]
46. Impact of different surgical procedures on survival outcomes of patients with adenocarcinoma of pancreatic neck.
Zheng Z; Tan C; Chen Y; Ping J; Wang M
PLoS One; 2019; 14(5):e0217427. PubMed ID: 31125386
[TBL] [Abstract][Full Text] [Related]
47. Pancreatic Carcinosarcoma Clinical Outcome Analysis of the National Cancer Institute Database.
Alhatem A; Quinn PL; Xia W; Chokshi RJ
J Surg Res; 2021 Mar; 259():62-70. PubMed ID: 33279845
[TBL] [Abstract][Full Text] [Related]
48. Early onset pancreatic malignancies: Clinical characteristics and survival associations.
Beeghly-Fadiel A; Luu HN; Du L; Shi C; McGavic DP; Parikh AA; Raskin L
Int J Cancer; 2016 Nov; 139(10):2169-77. PubMed ID: 27416564
[TBL] [Abstract][Full Text] [Related]
49. Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer.
Katz MH; Hu CY; Fleming JB; Pisters PW; Lee JE; Chang GJ
Arch Surg; 2012 Jun; 147(6):513-9. PubMed ID: 22351874
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
51. Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer.
Young JI; Mongoue-Tchokote S; Wieghard N; Mori M; Vaccaro GM; Sheppard BC; Tsikitis VL
Dis Colon Rectum; 2016 Apr; 59(4):306-15. PubMed ID: 26953989
[TBL] [Abstract][Full Text] [Related]
52. Stage III should be subclassified into Stage IIIA and IIIB in the American Joint Committee on Cancer (8
Yu HF; Zhao BQ; Li YC; Fu J; Jiang W; Xu RW; Yang HC; Zhang XJ
World J Gastroenterol; 2018 Jun; 24(22):2400-2405. PubMed ID: 29904247
[TBL] [Abstract][Full Text] [Related]
53. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.
Huang L; Balavarca Y; van der Geest L; Lemmens V; Van Eycken L; De Schutter H; Johannesen TB; Zadnik V; Primic-Žakelj M; Mägi M; Grützmann R; Besselink MG; Schrotz-King P; Brenner H; Jansen L
BMC Med; 2019 Mar; 17(1):66. PubMed ID: 30905320
[TBL] [Abstract][Full Text] [Related]
54. Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study.
Yadav S; Sharma P; Zakalik D
Am J Clin Oncol; 2018 May; 41(5):485-491. PubMed ID: 27322698
[TBL] [Abstract][Full Text] [Related]
55. Implications of Prolonged Time to Pancreaticoduodenectomy After Neoadjuvant Chemoradiation.
Teng A; Nguyen T; Bilchik AJ; O'Connor V; Lee DY
J Surg Res; 2020 Jan; 245():51-56. PubMed ID: 31401247
[TBL] [Abstract][Full Text] [Related]
56. Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer.
Shin JY; Yoon JK; Marwaha G
Lung; 2018 Jun; 196(3):351-358. PubMed ID: 29550987
[TBL] [Abstract][Full Text] [Related]
57. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium.
Groen JV; Sibinga Mulder BG; van Eycken E; Valerianova Z; Borras JM; van der Geest LGM; Capretti G; Schlesinger-Raab A; Primic-Zakelj M; Ryzhov A; van de Velde CJH; Bonsing BA; Bastiaannet E; Mieog JSD
Ann Surg Oncol; 2018 Nov; 25(12):3492-3501. PubMed ID: 30151560
[TBL] [Abstract][Full Text] [Related]
58. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity.
Swords DS; Mulvihill SJ; Brooke BS; Skarda DE; Firpo MA; Scaife CL
Surgery; 2019 Apr; 165(4):751-759. PubMed ID: 30551868
[TBL] [Abstract][Full Text] [Related]
59. Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma.
Ouaissi M; Frasconi C; Mege D; Panicot-Dubois L; Boiron L; Dahan L; Debourdeau P; Dubois C; Farge D; Sielezneff I
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):436-42. PubMed ID: 26256090
[TBL] [Abstract][Full Text] [Related]
60. Survival in pancreatic cancer: the best is yet to come.
Sauer BG; Shami VM
Gastrointest Endosc; 2010 Jul; 72(1):84-5. PubMed ID: 20620275
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
